Janjigian, Raoufmoghaddam et al. (2024) reported the DG-03 trial design, which enrolled treatment-naïve patients with HER2+ or HER2-low gastric cancer (including GEJA and esophageal adenocarcinoma). This evidence concerns the gene ERBB2 and gastric cancer.